Corrigendum

Corrigendum

York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandThe role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res. 2011;3:109-116. I...

Full description

Bibliographic Details
Main Authors: Zoellner Y, Balp MM, Gili Marco A
Format: Article
Language:English
Published: Dove Medical Press 2011-09-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/corrigendum-the-role-of-galenic-innovation-a8225
Description
Summary:York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandThe role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res. 2011;3:109-116. In the results section of the abstract, "...+15% in Germany for desferrioxamine vs deferasirox." should read "...+15% in Germany for deferasirox vs desferrioxamine." In the ‘Compliance' section, "...and +15% in Germany for desferrioxamine vs deferasirox." should read "...and +15% in Germany for deferasirox vs desferrioxamine."Original Article 
ISSN:1178-6981

Similar Items